PARP inhibitor–associated folate deficiency anemia

Blood Red Cells & Iron 2026 Open access

Read full text
Authors: Noa Rippel, D.I. Nathan, W. Fu, J. M. Liu, Ilan Shapira, P. Klein
DOI: 10.1016/j.brci.2026.100052
Cited by: 0
References: 21

Abstract

Following PARPi initiation for BRCA1/2 -related malignancies, at least 3.1% of patients developed marked folate deficiency anemia, precipitating hemoglobin decreases from 11.1 (IQR 9.9-12.1) to 7.0 g/dL (IQR 6.3-7.4) ( P < 0.001), PRBC transfusion dependence (62.5%), and cancer treatment disruptions (75%).

Fields of Study & Subjects

PARP inhibition in cancer therapy Folate and B Vitamins Research Hematological disorders and diagnostics

Publication details

Journal / source
Blood Red Cells & Iron
Volume
2
Issue
2
Pages
100052–100052
Publication date
12 January 2026
Language
EN